Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HELIX BIOPHARMA (HBP:TSE) -- Ignore unavailable to you. Want to Upgrade?

To: thewiz who wrote (186)	4/29/1999 7:57:00 PM
From: burner	Respond to of 193

Wiz---simply a good company and this move is impressive in the light of comparable biotech plays. Dan

To: thewiz who wrote (186)	5/19/1999 11:14:00 PM
From: burner	Read Replies (1) \| Respond to of 193

Helix BioPharma develops interferon-a cream Helix Biopharma Corp HBP Shares issued 13,776,415 May 18 close $1.36 Wed 19 May 99 News Release Dr. Marianna Foldvari reports An interferon-a cream to replace injections of this well-known antiviral drug is now being developed by Helix to combat the disease threat from the human papilloma virus (HPV). Helix has decided to pursue the development of the interferon-a cream with its proprietary BIPHASIX injectionless drug delivery technology to treat viral infections, beginning with HPV, as a result of successful preclinical studies. Interferon-a in an injectionless format is expected to result in lower health care costs and improved patient compliance. "The highly contagious HPV is one of the most common sexually transmitted diseases causing genital warts as well as being linked to cervical cancer. HPV has been shown to be present in 95 per cent of women with invasive cervical cancer," said Dr. Marianna Foldvari, Helix's director of pharmaceutical research. It is estimated that more than 24 million people in North America have HPV, and one million new cases of the disease are diagnosed annually according to American-based Centre for Disease Control. Current therapies to treat genital warts include freezing the warts off, caustic chemicals directly applied to the warts, surgery, and the use of creams and injections to stimulate the immune system against the virus. These therapies are only effective in approximately 50 per cent of the cases, and may have undesirable side effects. The company's BIPHASIX uses a unique, lipid-based, microencapsulation process, which is capable of delivering a wide variety of pharmaceuticals and vaccines of varying size, weight and solubilities. This technology is particularly well suited to biologically derived pharmaceuticals including DNA and proteins such as interferon and insulin. WARNING: The company relies upon litigation protection for "forward-looking" statements. (c) Copyright 1999 Canjex Publishing Ltd. canada-stockwatch.com